• Pfizer Inc., of New York, said it entered an agreement with Glaxosmithkline plc, of London, to explore the anticancer efficacy and safety of GSK’s trametinib (GSK1120212) combined with Pfizer’s palbociclib (PD-0332991) in a Phase I/II study in patients with advanced/metastatic melanoma.